Market Research Logo

Plasmid DNA Manufacturing Market - Size, Share, Outlook, and Opportunity Analysis, 2018- 2026

Plasmid DNA Manufacturing Market - Size, Share, Outlook, and Opportunity Analysis, 2018- 2026

Plasmid DNA (pDNA) can be used directly as a therapeutic agent in gene therapy or generation of vaccine antigens, and indirectly in a range of research applications. These applications include its use as a critical starting material for transient transfection to produce both viral-vector constructs such as lentivirus or Adeno-associated virus (AAV) and transient proteins in development such as monoclonal antibody. pDNA is used as a master-template product to support production of new and emerging biopharmaceutical products and processes including RNA, in-vitro protein production, and cell therapies.

Plasmids used as therapeutic agents tend to be relatively small in size (4.5– 6.0 kb and even down to 2.5 kb), requiring relatively low quantities to support early phase clinical trials (1–5 g of purified pDNA). These advantages make plasmid DNA more suitable to carry out late phase clinical trials.

Increasing demand for plasmid DNA (pDNA) and increasing research and development activities are major factors driving the plasmid DNA manufacturing market growth. For instance, in April 2018, PlasmidFactory GmbH & Co. KG acquired new laboratory space to expand research and development activities and production of plasmid DNA.

Cobra Biologics, a U.K.-based contract development and manufacturing organization (CDMO) has been producing plasmid DNA for a number of clinical applications for over 15 years at an approved site in the U.K. under the European Union (EU) clinical trials directive.

The company developed its own manufacturing process for production and purification of pDNA with related proprietary technologies, which include an antibiotic-free plasmid maintenance system, operator repressor titration (ORT), and cell-lysis technologies (2–4). Moreover, company successfully executed over 240 DNA programs with process development, manufacturing, and stability studies for over 35 different customers, globally. Generated plasmids have been used in clinical trials for gene therapy and vaccines as well as in viral vector production.

Moreover, large scale companies are actively focusing on strategic partnerships for drug development activity, which is expected to drive the market growth over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the plasmid DNA manufacturing market and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global plasmid DNA manufacturing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Cobra Biologics and Pharmaceutical Services, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Application Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, and Waisman Biomanufacturing
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, market expansion, and marketing tactics
  • The global plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the plasmid DNA manufacturing market
Detailed Segmentation:
  • Global Plasmid DNA Manufacturing Market, By Product Type:
  • High Quality (HQ) Plasmid DNA
  • GMP Grade Plasmid DNA
  • Non-GMP Grade Plasmid DNA
  • Global Plasmid DNA Manufacturing Market, By Application:
  • DNA Vaccines
  • Gene Therapy
  • Immunotherapy
  • Others
  • Global Plasmid DNA Manufacturing Market, By Region:
  • North America
  • By Product Type:
  • High Quality (HQ) Plasmid DNA
  • GMP Grade Plasmid DNA
  • Non-GMP Grade Plasmid DNA
  • By Application:
  • DNA Vaccines
  • Gene Therapy
  • Immunotherapy
  • Others
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Product Type:
  • High Quality (HQ) Plasmid DNA
  • GMP Grade Plasmid DNA
  • Non-GMP Grade Plasmid DNA
  • By Application:
  • DNA Vaccines
  • Gene Therapy
  • Immunotherapy
  • Others
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Product Type:
  • High Quality (HQ) Plasmid DNA
  • GMP Grade Plasmid DNA
  • Non-GMP Grade Plasmid DNA
  • By Application:
  • DNA Vaccines
  • Gene Therapy
  • Immunotherapy
  • Others
  • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Product Type:
  • High Quality (HQ) Plasmid DNA
  • GMP Grade Plasmid DNA
  • Non-GMP Grade Plasmid DNA
  • By Application:
  • DNA Vaccines
  • Gene Therapy
  • Immunotherapy
  • Others
  • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Product Type:
  • High Quality (HQ) Plasmid DNA
  • GMP Grade Plasmid DNA
  • Non-GMP Grade Plasmid DNA
  • By Application:
  • DNA Vaccines
  • Gene Therapy
  • Immunotherapy
  • Others
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Product Type:
  • High Quality (HQ) Plasmid DNA
  • GMP Grade Plasmid DNA
  • Non-GMP Grade Plasmid DNA
  • By Application:
  • DNA Vaccines
  • Gene Therapy
  • Immunotherapy
  • Others
  • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Cobra Biologics and Pharmaceutical Services *
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Highlights
  • Market Strategies
  • VGXI, Inc.
  • Aldevron
  • Kaneka Corporation
  • Nature Application Corporation
  • PlasmidFactory GmbH & Co. KG
  • Cell and Gene Therapy Catapult
  • Waisman Biomanufacturing.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Product Type
Market Snippet, By Application
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Market Trends
Impact Analysis
Key Highlights
PEST Analysis
PORTER’s Analysis
Mergers and Acquisitions
Epidemiology
4. Global Plasmid DNA Manufacturing Market, By Product Type, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017– 2026
Segment Trends
High Quality (HQ) Plasmid DNA
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Mn)
GMP Grade Plasmid DNA
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Mn)
Non-GMP Grade Plasmid DNA
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Mn)
5. Global Plasmid DNA Manufacturing Market, By Application, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017– 2026
Segment Trends
DNA Vaccines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Mn)
Gene Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Mn)
Immunotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Mn)
6. Global Plasmid DNA Manufacturing Market, By Region, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2026
North America
Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Mn)
U.S.
Canada
Latin America
Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Mn)
South Africa
Central Africa
North Africa
7. Competitive Landscape
Heat Map Analysis
Market Share Analysis
Company Profiles
Cobra Biologics and Pharmaceutical Services *
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
VGXI, Inc.
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Aldevron
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Kaneka Corporation
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Nature Application Corporation
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
PlasmidFactory GmbH & Co. KG
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Cell and Gene Therapy Catapult
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Waisman Biomanufacturing
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Analyst Views
8. Section
References
Research Methodology
About us and Sales Contact
*Browse 36 market data tables and 32 figures on "Plasmid DNA Manufacturing Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report